Literature DB >> 21696072

Intra-coronary bone marrow mononuclear cell transplantation in patients with ST-elevation myocardial infarction: a randomized controlled study.

Suphot Srimahachota1, Smonporn Boonyaratavej, Pairoj Rerkpattanapipat, Somjai Wangsupachart, Monravee Tumkosit, Udomsak Bunworasate, Thayapong Na Nakorn, Tanin Intragumtornchai, Pawinee Kupatawintu, Sunisa Pongam, Aem-Orn Saengsiri, Mantana Pothisri, Yeesoon Sukseri, Tanorm Bunprasert, Taworn Suithichaiyakul.   

Abstract

BACKGROUND: Stem cell transplantation is a potential treatment to improve left ventricular ejection fraction (LVEF) after ST elevation myocardial infarction (STEMI). However, the outcomes still are controversial.
OBJECTIVE: To determine the 6-month LVEF of the patients who underwent intra-coronary bone marrow mononuclear cell (BMC) transplantation in patients with STEMI compared with controlled subjects. MATERIAL AND
METHOD: After successful percutaneous coronary intervention (PCI) in STEMI patients who had LVEF was less than 50% were randomized to intra-coronary BMC transplantation or control. Bone marrow aspiration of 100 cc was performed in the morning. After cellprocessing for three hours, the suspension of BMC about 10 cc were infused to infracted area using standard PCI technique. Balloon occlusion for three minutes was performed during cell infusion. Cardiac magnetic resonance imaging was used to determine LVEF scar volume and LV volume before and six-month follow-up.
RESULTS: Between September 2006 and July 2008, 23patients (11 in BMC group and 12 in control group) were enrolled. Mean BMC count before transplant was 420 x 10(6) cell with 96% viability. At six-month follow-up, New York Heart Association function class significantly improved in both groups (2.3 +/- 0.6 to 1.2 +/- 0. 4 for BMC and 2.3 +/- 0.7 to 1.3 +/- 0.5 for control group) but no difference was seen between groups. However, scar volume, wall motion score index, and LVEF did not show improvement after six months in both groups (33.7 +/- 7.7 to 33.5 +/- 7.6 for BMC and 31.1 +/- 7.1 to 32.6 +/- 8.3 for control group). No complication was observed during the procedure.
CONCLUSION: BMC transplantation intra-coronary in patients with STEMI in KCMH was feasible and safe but LVEF improvement could not be demonstrated.

Entities:  

Mesh:

Year:  2011        PMID: 21696072

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  6 in total

1.  Clinical trials of cardiac repair with adult bone marrow- derived cells.

Authors:  Vinodh Jeevanantham; Mohammad R Afzal; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Methods Mol Biol       Date:  2013

Review 2.  Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis.

Authors:  Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circulation       Date:  2012-06-22       Impact factor: 29.690

Review 3.  Adult Bone Marrow Cell Therapy for Ischemic Heart Disease: Evidence and Insights From Randomized Controlled Trials.

Authors:  Muhammad R Afzal; Anweshan Samanta; Zubair I Shah; Vinodh Jeevanantham; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn
Journal:  Circ Res       Date:  2015-07-09       Impact factor: 17.367

4.  Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis.

Authors:  Seon Heui Lee; Jin Hyuk Hong; Kyoung Hee Cho; Jin-Won Noh; Hyun-Jai Cho
Journal:  Stem Cell Res Ther       Date:  2016-10-20       Impact factor: 6.832

5.  Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy.

Authors:  Upal Sengupta; Vinod Kumar; Ashok K Yadav; Neelam Marwaha; Harbir S Kohli; Vinay Sakhuja; Vivekanand Jha
Journal:  BMC Nephrol       Date:  2013-12-01       Impact factor: 2.388

6.  Bone Marrow Mononuclear Cells Transfer for Patients after ST-Elevated Myocardial Infarction: A Meta-Analysis of Randomized Control Trials.

Authors:  Jingyi Zhang; Li Lin; Wenxia Zong
Journal:  Yonsei Med J       Date:  2018-07       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.